Apnimed rises on Street initiations following IPO
Seeking Alpha News (Tue, 25-Aug 11:31 AM ET)
Apnimed, Inc. (APMD) Receives a Buy from LifeSci Capital
TipRanks (Tue, 25-Aug 6:28 AM ET)
TipRanks (Tue, 25-Aug 6:26 AM ET)
Globe Newswire (Mon, 3-Aug 4:35 PM ET)
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Apnimed trades on the NASDAQ stock market under the symbol APMD.
As of August 28, 2026, APMD stock price climbed to $29.71 with 522,333 million shares trading.
APMD has a market cap of $1.18 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that APMD belongs to (by Net Assets): VTI, VXF, VTWO, JDOC, VTWG.
APMD support price is $26.29 and resistance is $31.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APMD shares will trade within this expected range on the day.